Danish biotech leads the way  

New Ernst & Young report confirms Denmark's strong position in biotech

National newspaper Jyllands-Posten reports today that a new biotech survey "Beyond borders" from Ernst & Young reveals Denmark to be among the leaders for pipeline biotech products from stock exchange quoted companies. Denmark and UK top the table, with Sweden and Germany sixth and seventh respectively. The survey, which compared the research performance of quoted European biotech companies, showed that the Danish companies have 33 products under development compared with 13 in Sweden.


Last year, US and European biotech companies obtained almost DKK 80 billion (USD 9.6 billion) in funding, mainly from venture capital companies and shareholder capital. Ernst & Young report that the number of European biotech companies has doubled in the last 5 years, with turnover increasing 7-fold and market value tripling in the same period.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×